Literature DB >> 32130629

Complex I Controls Mitochondrial and Plasma Membrane Potentials in Nerve Terminals.

Seán M Kilbride1, Jayne E Telford1, Gavin P Davey2.   

Abstract

Reductions in the activities of mitochondrial electron transport chain (ETC) enzymes have been implicated in the pathogenesis of numerous chronic neurodegenerative disorders. Maintenance of the mitochondrial membrane potential (Δψm) is a primary function of these enzyme complexes, and is essential for ATP production and neuronal survival. We examined the effects of inhibition of mitochondrial ETC complexes I, II/III, III and IV activities by titrations of respective inhibitors on Δψm in synaptosomal mitochondria. Small perturbations in the activity of complex I, brought about by low concentrations of rotenone (1-50 nM), caused depolarisation of Δψm. Small decreases in complex I activity caused an immediate and partial Δψm depolarisation, whereas inhibition of complex II/III activity by more than 70% with antimycin A was required to affect Δψm. A similarly high threshold of inhibition was found when complex III was inhibited with myxothiazol, and inhibition of complex IV by more than 90% with KCN was required. The plasma membrane potential (Δψp) had a complex I inhibition threshold of 40% whereas complex III and IV had to be inhibited by more than 90% before changes in Δψp were registered. These data indicate that in synaptosomes, both Δψm and Δψp are more susceptible to reductions in complex I activity than reductions in the other ETC complexes. These findings may be of relevance to the mechanism of neuronal cell death in Parkinson's disease in particular, where such reductions in complex I activity are present.

Entities:  

Keywords:  Complex I; Energy thresholds; Membrane potentials; Mitochondria; Nerve terminal; Neurodegeneration

Year:  2020        PMID: 32130629     DOI: 10.1007/s11064-020-02990-8

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  41 in total

1.  Brain cytochrome oxidase in Alzheimer's disease.

Authors:  S J Kish; C Bergeron; A Rajput; S Dozic; F Mastrogiacomo; L J Chang; J M Wilson; L M DiStefano; J N Nobrega
Journal:  J Neurochem       Date:  1992-08       Impact factor: 5.372

2.  Complex I deficiency in Parkinson's disease frontal cortex.

Authors:  W Davis Parker; Janice K Parks; Russell H Swerdlow
Journal:  Brain Res       Date:  2007-11-01       Impact factor: 3.252

3.  Mitochondrial complex I deficiency in Parkinson's disease.

Authors:  A H Schapira; J M Cooper; D Dexter; J B Clark; P Jenner; C D Marsden
Journal:  J Neurochem       Date:  1990-03       Impact factor: 5.372

4.  Mitochondrial complex I deficiency in Parkinson's disease.

Authors:  A H Schapira; J M Cooper; D Dexter; P Jenner; J B Clark; C D Marsden
Journal:  Lancet       Date:  1989-06-03       Impact factor: 79.321

5.  Mitochondrial ND5 mutations in idiopathic Parkinson's disease.

Authors:  W Davis Parker; Janice K Parks
Journal:  Biochem Biophys Res Commun       Date:  2005-01-21       Impact factor: 3.575

6.  Chronic systemic pesticide exposure reproduces features of Parkinson's disease.

Authors:  R Betarbet; T B Sherer; G MacKenzie; M Garcia-Osuna; A V Panov; J T Greenamyre
Journal:  Nat Neurosci       Date:  2000-12       Impact factor: 24.884

7.  Biochemical pathophysiology of Parkinson's disease.

Authors:  O Hornykiewicz; S J Kish
Journal:  Adv Neurol       Date:  1987

Review 8.  Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds.

Authors:  K F Tipton; T P Singer
Journal:  J Neurochem       Date:  1993-10       Impact factor: 5.372

9.  Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis.

Authors:  J W Langston; P Ballard; J W Tetrud; I Irwin
Journal:  Science       Date:  1983-02-25       Impact factor: 47.728

10.  In a flurry of PINK, mitochondrial bioenergetics takes a leading role in Parkinson's disease.

Authors:  Anne N Murphy
Journal:  EMBO Mol Med       Date:  2009-05       Impact factor: 12.137

View more
  3 in total

1.  Preventing Axonal Sodium Overload or Mitochondrial Calcium Uptake Protects Axonal Mitochondria from Oxidative Stress-Induced Alterations.

Authors:  Bimala Malla; Carmen Infante-Duarte; Rebecca Ulshöfer; Helena Bros; Anja Erika Hauser; Raluca Aura Niesner; Friedemann Paul
Journal:  Oxid Med Cell Longev       Date:  2022-05-24       Impact factor: 7.310

2.  A Highly Selective In Vitro JNK3 Inhibitor, FMU200, Restores Mitochondrial Membrane Potential and Reduces Oxidative Stress and Apoptosis in SH-SY5Y Cells.

Authors:  Stephanie Cristine Hepp Rehfeldt; Stefan Laufer; Márcia Inês Goettert
Journal:  Int J Mol Sci       Date:  2021-04-02       Impact factor: 5.923

3.  Alzheimer's disease-causing presenilin-1 mutations have deleterious effects on mitochondrial function.

Authors:  Jihoon Han; Heejin Park; Chinmoyee Maharana; A-Ryeong Gwon; Jinsu Park; Seung Hyun Baek; Han-Gyu Bae; Yoonsuk Cho; Hark Kyun Kim; Jae Hoon Sul; Jeongmi Lee; Eunae Kim; Junsik Kim; Yongeun Cho; Sunyoung Park; Leon F Palomera; Thiruma V Arumugam; Mark P Mattson; Dong-Gyu Jo
Journal:  Theranostics       Date:  2021-08-17       Impact factor: 11.556

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.